Connected to: 14 advisory boards, 8 quant studies, 63 IDIs, 27 internal debriefs (no PHI).
Which HCP segments look under-penetrated given where recurrent pericarditis patients are actually showing up?
Based on the last 18 months of research, three segments stand out:
1. Community cardiology
High frequency of chest pain and pericarditis-like workups, but low spontaneous ARCALYST awareness. HCPs here tend to default to conventional anti-inflammatory regimens and express uncertainty about when escalation is appropriate.
2. Regional academic centers
Moderate patient volume with strong guideline familiarity, but low exposure to real-world ARCALYST data. Advisory boards highlight a desire for more outcomes data in "non-classic" presentations.
3. Rheumatology
Sees a subset of recurrent inflammatory cases that overlap with the RP population. Surveys show interest in IL-1 inhibition conceptually, but limited clarity on referral vs. initiation.
If the goal is near-term growth, a coordinated push into community cardiology + regional academic centers is likely to have the highest impact, with MA focused on diagnostic confidence and clear "when to escalate" triggers.
From an HQ perspective, what should Commercial and MA respectively emphasize for community cardiology?
For community cardiology, the research suggests three priorities:
Commercial
• Simple framing of labeled use and access expectations.
• Clear, referral-friendly messaging to centers of excellence.
Medical Affairs
• Diagnostic recognition cues and differential diagnosis support.
• Evidence around escalation triggers and outcomes in recurrent cases.
• Reactive scientific support for complex or atypical presentations.